

# COMPANY NOTE

## Nexstim OYJ (NXTMH-FI)

FY2018 results reflect growing focus on therapy

### KEY TAKEAWAY

Nexstim reported FY2018 sales of €2.7m, broadly flat vs. €2.6m in FY2017, as a 127% increase in US sales was largely offset by a -56% decline in Europe. The company reported solid installed-base growth, bringing the total number of installed Navigated Brain Stimulation ("NBS") and Navigated Brain Therapy ("NBT") systems to 160 (+10 YoY) and 10 (+10 YoY), respectively. As a result of the increased focus on NBT commercialisation, we are revising our sales forecasts for FY2019E and out-years to account for pay-per-use ("PPY") sales. YE2018 cash stood at €7.2m, which should allow the company to fund operations until YE2019E. Nexstim also announced a potential divestment of its NBS business and will provide an update following the AGM on March 25th. We continue to believe that Nexstim is well-positioned to find broad adoption across the depression market, affecting more than 10 million individuals in the US alone. We reiterate both our OUTPERFORM recommendation and €8.40 target price ("TP").

### FY2018 results reflect successful commercial launch of NBT for depression

Despite reporting flat sales growth, the operating loss increased by 13% to €6.3m due largely to investments into the sales infrastructure in the US. Personnel expenses grew by 18% YoY as a result of the addition of 6 new sales people in the US, bringing the total sales staff to 10. The expanding US team should allow the company to increase sales rapidly in 2019E. Following the distribution agreement with Hong Kong-based Ampere Medical in October 2018, Nexstim recently announced the signing of an additional agreement with Canadian Health Solutions to bring NBT for depression to the Canadian market.

### Adjusting 2019E sales and beyond to reflect NBT pay-per-use model

In light of the FY2018 results we adjust our forecasts to reflect expected delays in monetisation associated with the PPY sales model used in the US. We have also adjusted our NBS sales forecast in line with historic growth to reflect an increased commercial focus on the therapy business. As a result of our adjustments, we have trimmed 2019E and out-year sales, and now expect profitability in 2022E (vs. 2021E prev.). Due to the inherent revenue lag associated with the PPY model, we anticipate sales on the back of the growth in NBT installed base to be increasingly realised from 2019E.

### We maintain our target price of €8.40

We value Nexstim based on a DCF approach using a WACC of 14%, which yields a fair value of €8.40 per share. We continue to believe that Nexstim is well-positioned to enter a period of accelerated growth as the therapy business starts to gain traction and recurring revenues from systems consigned in 2018 begin to be realised from 2019E. The main risk to our TP are low adoption and utilisation rates, which could lead to lower than expected top-line growth. We reiterate both our OUTPERFORM recommendation and €8.40 target price

EUR	2016A	2017A	2018A	2019E	2020E
Sales	2	3	3	4	8
EBIT	(7)	(6)	(6)	(6)	(5)
Net Profit					
FY Dec	(7)	(7)	(6)	(6)	(5)

Source: Company data, goetzpartners Research estimates. Warning Note: Past performance and forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations.

## OUTPERFORM

Target Price €8.40  
Current Price €0.85

### FINANCIAL SUMMARY

Net Cash/Debt (M): 0.20

### MARKET DATA

Current Price: €0.85  
Target Price: €8.40  
52 Week Range: €7.43 - €0.50  
Total Enterprise Value: 4  
Market Cap (M): 3  
Shares Out (M): 3.3  
Float (M): 84.5  
Average Daily Volume: 5,710

## EQUITY RESEARCH

MARTIN PIEHLMEIER  
Analyst  
T +44 (0) 203 859 7724  
martin.piehlmeier@goetzpartners.com

GOETZPARTNERS HEALTHCARE RESEARCH TEAM  
Research Team  
T +44 (0) 203 859 7725  
healthcareresearch@goetzpartners.com

ERLAND STERNBY  
Marketing Sales  
T +44 (0) 203 859 7725  
erland.sternby@goetzpartners.com

### PRICE PERFORMANCE



## Revenues broadly in line with forecast but operating and net loss smaller than expected

Nexstim reported smaller operating and net losses vs. our forecasts, as marginally lower sales were more than offset by lower operating expenses, particularly personnel and other costs.

**CHART 1: FY2018 variance table (€m)**

P&L item	FY2017A	FY2018A	YoY growth	FY2018E	Δ vs. GPSLe
<b>Revenue</b>	<b>2.6</b>	<b>2.7</b>	1.0%	<b>3.1</b>	(14.9%)
COGS	(0.5)	(0.7)	36.1%	(0.9)	(19.2%)
<b>Gross profit</b>	<b>(0.5)</b>	<b>2.0</b>	(475.8%)	<b>2.3</b>	(13.2%)
Personnel costs	(3.3)	(3.9)	18.1%	(4.5)	(12.5%)
Other costs	(4.0)	(3.9)	(3.1%)	(5.5)	(28.8%)
D&A expenses	(0.3)	(0.4)	24.2%	(0.1)	296.5%
<b>Total costs &amp; operating expenses</b>	<b>(7.7)</b>	<b>(8.3)</b>	7.3%	<b>(10.1)</b>	(18.1%)
<b>EBIT</b>	<b>(8.2)</b>	<b>(6.3)</b>	(23.3%)	<b>(7.8)</b>	(19.5%)
Interest expenses	(1.7)	0.2	(109.4%)	(1.2)	(113.6%)
<b>Profit/Loss before tax</b>	<b>(10.0)</b>	<b>(6.2)</b>	(38.3%)	<b>(9.0)</b>	(32.0%)
Income tax	(0.0)	(0.0)	(38.3%)	-	-
<b>Net income/loss</b>	<b>(10.0)</b>	<b>(6.2)</b>	(38.3%)	<b>(9.0)</b>	(32.0%)

Source: Company data, goetzpartners Research estimates

Warning Note: Past performance and forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations

## Adjusting 2019E sales and beyond to reflect NBT pay per use sales model

We have lowered our 2019E – 2023E sales forecasts due to the inclusion of the pay-per-use sales structure into our NBT revenue estimates, which delays revenue generation due to the absence of upfront payments. Furthermore, we have trimmed our NBS sales forecast in line with historic growth to reflect an increased emphasis on the commercialisation of NBT systems in the future. This was partially offset by a lowering of our personnel expense forecasts. We now expect Nexstim to reach sustained profitability in 2022E vs. 2021E previously.

**CHART 2: Changes to our forecasts 2019E – 2023E (€m)**

Revenue	2019E	2020E	2021E	2022E	2023E
Old	5.2	10.2	19.5	28.0	35.3
New	4.4	8.3	15.1	23.3	30.9
change	(14.6%)	(18.8%)	(22.5%)	(16.7%)	(12.6%)
Personnel costs	2019E	2020E	2021E	2022E	2023E
Old	(7.0)	(8.1)	(9.3)	(10.6)	(12.2)
New	(4.9)	(5.6)	(6.4)	(7.4)	(8.5)
change	(30.4%)	(30.4%)	(30.4%)	(30.4%)	(30.4%)
% revenue	(110.0%)	(67.8%)	(42.6%)	(31.8%)	(27.6%)
Other costs	2019E	2020E	2021E	2022E	2023E
Old	(2.0)	(2.3)	(2.6)	(3.0)	(3.5)
New	(4.4)	(5.1)	(5.9)	(6.7)	(7.7)
change	121.5%	121.5%	121.5%	121.5%	121.5%
% revenue	(100.0%)	(61.6%)	(38.7%)	(28.9%)	(25.1%)
Operating profit/(loss)	2019E	2020E	2021E	2022E	2023E
Old	(5.3)	(2.9)	2.6	7.2	10.6
New	(6.2)	(5.1)	(2.3)	1.3	4.4
change	17.1%	73.9%	(187.1%)	(81.6%)	(58.2%)
% revenue	(140.7%)	(61.6%)	(15.0%)	5.7%	14.4%
Net income	2019E	2020E	2021E	2022E	2023E
Old	(6.8)	(4.4)	1.1	4.7	7.4
New	(6.1)	(4.9)	(2.1)	1.2	3.7
change	(11.0%)	11.4%	(301.2%)	(74.8%)	(50.4%)
% revenue	(137.1%)	(59.7%)	(14.0%)	5.1%	11.9%

Source: goetzpartners Research estimates

Warning Note: Forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations.

## Financial models

**CHART 3: Nexstim profit & loss model**

Profit & Loss Statement		2016A	2017A	2018A	2019E	2020E	2021E	2022E	2023E	2024E	2025E	
Dec YE (€m except EPS)		units	31-Dec-16	31-Dec-17	31-Dec-18	31-Dec-19	31-Dec-20	31-Dec-21	31-Dec-22	31-Dec-23	31-Dec-24	31-Dec-25
<b>Revenue</b>	€m	<b>2.5</b>	<b>2.6</b>	<b>2.7</b>	<b>4.4</b>	<b>8.3</b>	<b>15.1</b>	<b>23.3</b>	<b>30.9</b>	<b>38.0</b>	<b>45.2</b>	
growth	%	(2%)	7%	1%	66%	87%	83%	54%	32%	23%	19%	
COGS	€m	(0.7)	(0.5)	(0.7)	(1.1)	(2.0)	(3.7)	(5.7)	(7.6)	(9.3)	(11.1)	
% sales	%	28%	20%	27%	26%	25%	25%	25%	25%	25%	25%	
growth	%	(16%)	(24%)	36%	60%	79%	83%	54%	32%	23%	19%	
<b>Gross profit</b>	€m	<b>1.8</b>	<b>2.1</b>	<b>2.0</b>	<b>3.3</b>	<b>6.2</b>	<b>11.4</b>	<b>17.6</b>	<b>23.3</b>	<b>28.7</b>	<b>34.1</b>	
gross margin	%	72%	80%	73%	74%	75%	75%	75%	75%	75%	75%	
Personnel costs	€m	(4.3)	(3.3)	(3.9)	(4.9)	(5.6)	(6.4)	(7.4)	(8.5)	(9.8)	(11.3)	
% sales	%	171%	126%	147%	110%	68%	43%	32%	28%	26%	25%	
growth	%	7%	(22%)	18%	24%	15%	15%	15%	15%	15%	15%	
Other costs	€m	(3.9)	(4.0)	(3.9)	(4.4)	(5.1)	(5.9)	(6.7)	(7.7)	(8.9)	(10.2)	
% sales	%	156%	153%	147%	100%	62%	39%	29%	25%	23%	23%	
growth	%	(47%)	5%	(3%)	13%	15%	15%	15%	15%	15%	15%	
D&A expenses	€m	(0.4)	(0.3)	(0.4)	(0.2)	(0.6)	(1.4)	(2.1)	(2.6)	(2.7)	(2.7)	
% sales	%	15%	13%	16%	5%	8%	9%	9%	8%	7%	6%	
growth	%	(53%)	(8%)	24%	(46%)	176%	120%	52%	22%	3%	1%	
<b>Total costs &amp; operating expenses</b>	€m	<b>(8.5)</b>	<b>(7.7)</b>	<b>(8.3)</b>	<b>(9.5)</b>	<b>(11.3)</b>	<b>(13.7)</b>	<b>(16.3)</b>	<b>(18.8)</b>	<b>(21.4)</b>	<b>(24.2)</b>	
<b>EBITDA</b>	€m	<b>(6.3)</b>	<b>(5.3)</b>	<b>(5.9)</b>	<b>(6.0)</b>	<b>(4.5)</b>	<b>(0.9)</b>	<b>3.4</b>	<b>7.0</b>	<b>9.9</b>	<b>12.6</b>	
margin	%	(255%)	(198%)	(220%)	(136%)	(54%)	(6%)	15%	23%	26%	28%	
growth	%	(34%)	(17%)	12%	2%	(26%)	(80%)	(482%)	105%	42%	26%	
<b>EBIT</b>	€m	<b>(6.7)</b>	<b>(5.6)</b>	<b>(6.3)</b>	<b>(6.2)</b>	<b>(5.1)</b>	<b>(2.3)</b>	<b>1.3</b>	<b>4.4</b>	<b>7.3</b>	<b>9.9</b>	
margin	%	(270%)	(211%)	(236%)	(141%)	(62%)	(15%)	6%	14%	19%	22%	
growth	%	(35%)	(16%)	13%	(1%)	(18%)	(55%)	(158%)	236%	64%	35%	
Net interest income/ (expense)		(0.0)	(1.7)	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	
<b>Profit/Loss before tax</b>	€m	<b>(6.7)</b>	<b>(7.3)</b>	<b>(6.2)</b>	<b>(6.1)</b>	<b>(4.9)</b>	<b>(2.1)</b>	<b>1.5</b>	<b>4.6</b>	<b>7.4</b>	<b>10.0</b>	
% sales	%	(271%)	(277%)	(230%)	(137%)	(60%)	(14%)	6%	15%	20%	22%	
growth	%	(32%)	9%	(16%)	(1%)	(19%)	(57%)	(170%)	210%	62%	35%	
Income tax	€m	0.0	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.3)	(0.9)	(1.5)	(2.0)	
Tax rate	%	(0%)	0%	0%	20%	20%	20%	20%	20%	20%	20%	
<b>Net income/loss</b>	€m	<b>(6.7)</b>	<b>(7.3)</b>	<b>(6.2)</b>	<b>(6.1)</b>	<b>(4.9)</b>	<b>(2.1)</b>	<b>1.2</b>	<b>3.7</b>	<b>6.0</b>	<b>8.0</b>	

### EPS calculation

<b>Earnings per share (basic)</b>	€	<b>(0.143)</b>	<b>(0.079)</b>	<b>(1.931)</b>	<b>(1.867)</b>	<b>(1.516)</b>	<b>(0.650)</b>	<b>0.364</b>	<b>1.131</b>	<b>1.832</b>	<b>2.467</b>
growth	%	(88%)	(45%)	2356%	(3%)	(19%)	(57%)	(156%)	210%	62%	35%
<b>Earnings per share (diluted)</b>	€	<b>(0.085)</b>	<b>(0.055)</b>	<b>(1.389)</b>	<b>(1.370)</b>	<b>(1.113)</b>	<b>(0.477)</b>	<b>0.267</b>	<b>0.830</b>	<b>1.345</b>	<b>1.811</b>
growth	%	(92%)	(35%)	2420%	(1%)	(19%)	(57%)	(156%)	210%	62%	35%
Avg. number of shares (basic)	m	47.1	93.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.3
Number of shares (diluted)	m	78.8	132.9	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4

Source: Company data, goetzpartners Research estimates

Warning Note: Past performance and forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations

CHART 4: Nexstim balance sheet model

Balance Sheet	2016A	2017A	2018A	2019E	2020E	2021E	2022E	2023E	2024E	2025E
Dec YE (€m)	31-Dec-16	31-Dec-17	31-Dec-18	31-Dec-19	31-Dec-20	31-Dec-21	31-Dec-22	31-Dec-23	31-Dec-24	31-Dec-25
<b>ASSETS</b>										
<b>CURRENT ASSETS</b>	<b>9.5</b>	<b>10.3</b>	<b>8.8</b>	<b>8.3</b>	<b>8.9</b>	<b>5.1</b>	<b>7.0</b>	<b>11.6</b>	<b>19.0</b>	<b>27.4</b>
Cash and cash equivalents	8.2	8.5	7.2	6.5	6.6	1.9	2.5	5.8	11.8	18.5
Inventories	0.3	0.4	0.3	0.5	1.0	1.9	3.2	4.5	6.0	7.5
Accounts receivable	1.1	1.5	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
<b>NON-CURRENT ASSETS</b>	<b>0.9</b>	<b>0.7</b>	<b>0.9</b>	<b>1.6</b>	<b>2.5</b>	<b>3.6</b>	<b>4.1</b>	<b>4.3</b>	<b>4.3</b>	<b>4.3</b>
<b>Tangible assets, net</b>	<b>0.2</b>	<b>0.2</b>	<b>0.5</b>	<b>0.6</b>	<b>1.0</b>	<b>1.8</b>	<b>2.0</b>	<b>1.8</b>	<b>1.6</b>	<b>1.4</b>
Goodwill	-	-	-	-	-	-	-	-	-	-
<b>Intangible assets, net</b>	<b>0.7</b>	<b>0.5</b>	<b>0.4</b>	<b>1.0</b>	<b>1.4</b>	<b>1.8</b>	<b>2.2</b>	<b>2.5</b>	<b>2.7</b>	<b>2.9</b>
Other non-current assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>TOTAL ASSETS</b>	<b>10.4</b>	<b>11.0</b>	<b>9.7</b>	<b>9.9</b>	<b>11.4</b>	<b>8.7</b>	<b>11.1</b>	<b>15.9</b>	<b>23.4</b>	<b>31.7</b>
<b>LIABILITIES</b>										
<b>CURRENT LIABILITIES</b>	<b>2.1</b>	<b>1.8</b>	<b>2.8</b>	<b>3.2</b>	<b>4.0</b>	<b>5.6</b>	<b>7.4</b>	<b>9.1</b>	<b>10.7</b>	<b>12.3</b>
Bank loans	-	-	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
Accounts payable	0.4	1.0	0.6	1.0	1.8	3.4	5.2	6.9	8.5	10.1
Short-term debt	1.0	0.1	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other current liabilities	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
<b>NON-CURRENT LIABILITIES</b>	<b>3.8</b>	<b>3.7</b>	<b>7.2</b>	<b>6.1</b>	<b>4.7</b>	<b>2.6</b>	<b>2.0</b>	<b>1.4</b>	<b>1.3</b>	<b>-</b>
Long-term debt	2.5	3.4	7.1	6.1	4.7	2.6	2.0	1.4	1.3	-
Capital loans	1.3	0.3	0.1	-	-	-	-	-	-	-
Other non-current liabilities	0.0	0.0	-	-	-	-	-	-	-	-
<b>TOTAL LIABILITIES</b>	<b>5.9</b>	<b>5.5</b>	<b>10.0</b>	<b>9.2</b>	<b>8.7</b>	<b>8.1</b>	<b>9.4</b>	<b>10.5</b>	<b>11.9</b>	<b>12.3</b>
<b>EQUITY</b>										
<b>SHAREHOLDERS EQUITY</b>	<b>4.5</b>	<b>5.5</b>	<b>(0.3)</b>	<b>0.6</b>	<b>2.7</b>	<b>0.6</b>	<b>1.8</b>	<b>5.4</b>	<b>11.4</b>	<b>19.4</b>
Share capital	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Reserves	31.7	38.5	39.5	46.5	53.5	53.5	53.5	53.5	53.5	53.5
Retained earnings & other	(27.3)	(33.1)	(39.9)	(45.9)	(50.9)	(53.0)	(51.8)	(48.1)	(42.2)	(34.1)
<b>TOTAL LIABILITIES &amp; SHAREHOLDERS' EQUITY</b>	<b>10.4</b>	<b>11.0</b>	<b>9.7</b>	<b>9.9</b>	<b>11.4</b>	<b>8.7</b>	<b>11.1</b>	<b>15.9</b>	<b>23.4</b>	<b>31.7</b>

Source: Company data, goetzpartners Research estimates

Warning Note: Past performance and forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations

**CHART 5: Nexstim cash flow model**

Cash Flow Statement	2016A	2017A	2018A	2019E	2020E	2021E	2022E	2023E	2024E	2025E
Dec YE (€m)	31-Dec-16	31-Dec-17	31-Dec-18	31-Dec-19	31-Dec-20	31-Dec-21	31-Dec-22	31-Dec-23	31-Dec-24	31-Dec-25
<b>OPERATING CASH FLOW</b>										
Net income/loss	(6.7)	(7.3)	(6.2)	(6.1)	(4.9)	(2.1)	1.2	3.7	6.0	8.0
Depreciation	0.3	0.3	0.2	0.2	0.5	1.2	1.8	2.2	2.3	2.3
Amortisation	0.0	0.0	0.3	0.1	0.1	0.2	0.3	0.3	0.4	0.4
Other	(0.4)	3.3	(0.8)	-	-	-	-	-	-	-
<b>Changes in working capital</b>	<b>(0.4)</b>	<b>(1.6)</b>	<b>0.7</b>	<b>0.2</b>	<b>0.4</b>	<b>0.6</b>	<b>0.6</b>	<b>0.3</b>	<b>0.2</b>	<b>0.0</b>
Changes in inventories				(0.2)	(0.5)	(1.0)	(1.3)	(1.3)	(1.4)	(1.6)
Changes in receivables				-	-	-	-	-	-	-
Changes in payables				0.4	0.9	1.5	1.8	1.7	1.6	1.6
<b>Changes in other operating assets/liabilities</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>NET CASH USED IN OPERATING ACTIVITIES</b>	<b>(7.2)</b>	<b>(5.3)</b>	<b>(5.8)</b>	<b>(5.7)</b>	<b>(3.9)</b>	<b>(0.2)</b>	<b>3.8</b>	<b>6.6</b>	<b>8.8</b>	<b>10.7</b>
<b>CASH FLOW FROM INVESTING</b>										
Payments for short-term investments	-	-	-	-	-	-	-	-	-	-
Proceeds from short-term investments	-	-	-	-	-	-	-	-	-	-
Investments in PP&E	-	-	-	(0.3)	(0.9)	(1.9)	(2.0)	(2.1)	(2.1)	(2.1)
Investments in intangibles	(0.3)	(0.1)	(0.6)	(0.6)	(0.6)	(0.6)	(0.6)	(0.6)	(0.6)	(0.6)
<b>Net cash provided by investing activities</b>	<b>(0.3)</b>	<b>(0.1)</b>	<b>(0.6)</b>	<b>(0.9)</b>	<b>(1.5)</b>	<b>(2.5)</b>	<b>(2.6)</b>	<b>(2.7)</b>	<b>(2.7)</b>	<b>(2.7)</b>
<b>CASH FLOW FROM FINANCING</b>										
Equity share issue	7.7	6.8	1.0	7.0	7.0	-	-	-	-	-
Proceeds from borrowings	1.1	-	4.5	-	-	-	-	-	-	-
Repayment of borrowings	-	(0.9)	-	(1.1)	(1.4)	(2.1)	(0.6)	(0.6)	(0.1)	(1.3)
Dividends	-	-	-	-	-	-	-	-	-	-
Other	0.0	(0.1)	(0.4)	-	-	-	-	-	-	-
<b>Net cash provided by financing activities</b>	<b>8.8</b>	<b>5.7</b>	<b>5.1</b>	<b>5.9</b>	<b>5.6</b>	<b>(2.1)</b>	<b>(0.6)</b>	<b>(0.6)</b>	<b>(0.1)</b>	<b>(1.3)</b>
Net change in cash and cash equivalents	1.3	0.3	(1.3)	(0.7)	0.1	(4.8)	0.6	3.3	6.0	6.8
Effect of exchange rate on cash and cash equivalents	-	-	-	-	-	-	-	-	-	-
Cash and cash equivalents, beginning of period	6.9	8.2	8.5	7.2	6.5	6.6	1.9	2.5	5.8	11.8
<b>Cash and cash equivalents, end of period</b>	<b>8.2</b>	<b>8.5</b>	<b>7.2</b>	<b>6.5</b>	<b>6.6</b>	<b>1.9</b>	<b>2.5</b>	<b>5.8</b>	<b>11.8</b>	<b>18.5</b>

Source: Company data, goetzpartners Research estimates

Warning Note: Past performance and forecasts are not a reliable indicator of future results or performance. The return may increase or decrease as a result of currency fluctuations

## COMPANY DESCRIPTION

Nexstim, a medical technology company, provides treatment for patients with depression through the use of non-invasive brain stimulation. The company offers a navigated brain stimulation ("NBS") system, a navigated transcranial magnetic stimulation device for pre-surgical mapping of the speech and motor cortices. The company also markets a navigated brain therapy ("NBT") system for the treatment of major depressive disorder ("MDD"). Nexstim was founded in 2000 and is headquartered in Helsinki, Finland.

## Peer Group Analysis

### SWOT

**Strengths** - Validated technology. Existing NBS business with potential to grow. Very profitable NBT business model in lucrative market.

**Weakness** - High cost base compared to existing sales level. Lack of financial resources to fully commercialise the technology.

**Opportunities** - Strategic co-operations and sales partnerships outside Europe and US. New therapeutic indications for NBT (pain) and use of the technology as a platform. M&A could lead to faster commercialisation and sales growth.

**Threats** - New emerging competition with bigger financial resources. Due to the company history and low share price, the company may end up being acquired at below fair value.

## Important Disclosures: Non-Independent Research

### Analyst Certification

I, Martin Piehlmeier, hereby certify that the views regarding the companies and their securities expressed in this research report are accurate and are truly held. I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this research report.

### Meaning of goetzpartners Research Ratings

goetzpartners securities Limited ("GPSL") publishes investment recommendations, which reflect the analyst's assessment of a stock's potential relative return. Our research offers 4 recommendations or 'ratings':

**OUTPERFORM** - Describes stocks that we expect to provide a relative return (price appreciation plus yield) of 15% or more within a 12-month period.

**NEUTRAL** - Describes stocks that we expect to provide a relative return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.

**UNDERPERFORM** - Describes stocks that we expect to provide a relative negative return (price appreciation plus yield) of 10% or more within a 12-month period.

**NON-RATED** – Describes stocks on which we provide general discussion and analysis of both up and downside risks but on which we do not give an investment recommendation.

### Companies Mentioned in this report

- (AMPERE MEDICAL LIMITED (PRIVATE COMPANY))
- (CANADIAN HEALTH SOLUTIONS INC. (PRIVATE COMPANY))
- Healthcare (HLTH)
- Medical Technology (MT)
- Nexstim OYJ (NXTMH-FI)

### Valuation Methodology

GPSL's methodology for assigning recommendations may include the following: market capitalisation, maturity, growth / value, volatility and expected total return over the next 12 months. The target prices are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

### Frequency

This research will be reviewed at a frequency of 3 months. Any major changes to the planned frequency of coverage will be highlighted in future research reports.

### Conflicts of interest

GPSL is required to disclose any conflicts of interest which may impair the firm's objectivity with respect to any research recommendations contained herein. Please click on the link to view the latest version of our [Conflicts of Interest policy](#).

We are also required to disclose any shareholdings of the firm or our affiliates in any relevant issuers which exceed 5% of the total issued share capital or any other significant financial interests held:

GPSL shareholdings in relevant issuers >5% - None.

GPSL wishes to disclose that it is party to a formal client agreement with Nexstim OYJ relating to the provision of advice and equity research services.

To avoid potential conflicts of interest arising, restrictions on personal account dealing are placed on analysts and other staff. The firm's personal account dealing policy expressly prohibits staff and / or relevant connected persons from dealing in the securities of a relevant issuer. Analysts must not trade in a manner contrary to their published recommendation or deal ahead of the publication of any research report.

To comply with the regulatory requirement to disclose. We disclose the monthly proportion of recommendations that are OUTPERFORM, NEUTRAL, UNDERPERFORM and NON-RATED. We also disclose a summary of the history of our analysts' investment recommendations (in accordance with EU MAR rules effective 3rd July 2016). goetzpartners publishes this information on the following link: [Research Summary](#).

### Country-Specific Disclosures


United Kingdom: goetzpartners securities Limited ("GPSL") is authorised and regulated by the Financial Conduct Authority ("FCA"); registered in England and Wales No. 04684144; registered office: The Stanley Building, 7 Pancras Square, London, N1C 4AG; telephone +44 (0)20 3859 7725. GPSL's FCA Firm Reference Number is: 225563. In the United Kingdom and European Economic Area, this research

report has been prepared, issued and / or approved for distribution by GPSL and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This marketing communication is classed as 'non-independent research' and, as such, has not been prepared in accordance with legal requirements designed to promote the independence of investment research. GPSL has adopted a Conflicts of Interest management policy in connection with the preparation and publication of research, the details of which are available upon request in writing to the Compliance Officer or on the web link above in the Conflicts of Interest section above. GPSL may allow its analysts to undertake private consultancy work. GPSL's conflicts management policy sets out the arrangements that the firm employs to manage any potential conflicts of interest that may arise as a result of such consultancy work.

**Other EU Investors:** This research report has been prepared and distributed by GPSL. This research report is a marketing communication for the purposes of Directive 2004/39/EC (MiFID). It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. GPSL is authorised and regulated in the United Kingdom by the FCA in connection with its distribution and for the conduct of its investment business in the European Economic Area. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients. Persons who are unsure of which investor category applies to them should seek professional advice before placing reliance upon or acting upon any of the recommendations contained herein. The registered address of GPSL is The Stanley Building, 7 Pancras Square, London, N1C 4AG. Tel: +44 (0)20 3859 7725.

**U.S. PERSONS:** This research report has been prepared by GPSL, which is authorised to engage in securities activities in England and Wales and to conduct designated investment business in the European Economic Area. GPSL is not a registered broker-dealer in the United States of America and therefore is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution in the United States solely to "major U.S. institutional investors" as defined in Rule 15a-6 under the Securities Exchange Act of 1934.

**Other countries:** Laws and regulations of other countries may also restrict the distribution of this research report. Persons in possession of research publications should inform themselves about possible legal restrictions and observe them accordingly.



## Risks

This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5). Information relating to any company or security is for information purposes only and should not be interpreted as a solicitation to buy or sell any security or to make any investment. The information in this research report has been compiled from sources believed to be reliable, but it has not been independently verified. No representation is made as to its accuracy or completeness, no reliance should be placed on it and no liability is accepted for any loss arising from reliance on it, except to the extent required by the applicable law. All expressions of opinion are subject to change without notice. Opinions, projections, forecasts or estimates may be personal to the author and may not reflect the opinions of goetzpartners securities Limited ("GPSL"). They reflect only the current views of the author at the date of the research report and are subject to change without notice. GPSL's research reports are not intended for Retail Clients as defined by the FCA. This research report is intended for professional clients only. Research reports are for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. The analysis, opinions, projections, forecasts and estimates expressed in research reports were in no way affected or influenced by the issuer. The authors of research reports benefit financially from the overall success of GPSL. The investments referred to in research reports may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations. Any loss or other consequence arising from the use of the material contained in a research report shall be the sole and exclusive responsibility of the investor and GPSL accepts no liability for any such loss or consequence. In the event of any doubt regarding any investment, recipients should contact their own investment, legal and /



or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in research reports may not be readily liquid investments which may be difficult to sell or realise. Past performance and forecasts are not a reliable indicator of future results or performance. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in research publications may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. Some of the information or data in this research report may rely on figures denominated in a currency other than that of GBP (the currency should be stated), the return may increase or decrease as a result of currency fluctuations. International investment includes risks related to political and economic uncertainties of foreign countries, as well as currency risk. To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of research reports or their contents.

GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they are monitored for regulatory and training purposes.

## Compensation

GPSL has received compensation from Nexstim OYJ for the provision of research and advisory services within the previous twelve months.

### NXTMH-FI

€8.40 | Company Update

12 March 2019

goetzpartners securities Limited  
The Stanley Building, 7 Pancras Square | London N1C 4AG | UK

[www.goetzpartnerssecurities.com](http://www.goetzpartnerssecurities.com)